$71.38

0.10 (0.14%)

7/23/2008 4:00 PM

Biogen Idec, Inc. (BIIB)

CAPS Rating:

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating BIIB

Add Stock to Watchlist

What the Community Thinks

Total Members

487 Outperforms

43 Underperforms

All-Stars

173 Outperforms

8 Underperforms

Wall Street

6 Outperforms

2 Underperforms

Members bullish on BIIB are also bullish on:

Members bearish on BIIB are also bearish on:

Ticker Tags

Biotechnology (294), Cambridge (4), Massachusetts (16), Optionable (32), S&P 500 (481), Rule Breakers Universe (161), Dermatology (7), Large Cap (467), Neuroscience (8), Nasdaq 100 (99), Major 2005 Lawsuit (8)
Suggest a tag

Biogen Idec, Inc. At A Glance

Current Price:	$71.38
Last Trade Time:	7/23/2008 4:00 PM
Open:	$71.41
Previous Close:	$71.28
Daily Range:	$70.00 - $72.34
52-Week Range:	$53.65 - $84.75
Volume:	5,535,297
Market Cap:	$20.69B
P/E Ratio:	30.33
Compare Our Special Broker Offers!

Stock Trends

BIIB VS S&P 500 (SPY)

News & Discussion Boards

Other News Headlines for BIIB

Biogen Idec's 2Q profit rises 11 percent
7/22/2008 4:55:00 PM - AP
Summary Box: Biogen Idec earnings
7/22/2008 11:42:00 AM - AP
Earnings roundup: DuPont, Biogen Idec
7/22/2008 10:31:00 AM - AP
Outlook roundup: Avery Dennison, Biogen Idec
7/22/2008 10:21:00 AM - AP

More Headlines...

Top Bull Pitch

Recs

1 Biogen Idec, Inc. (BIIB)

Avatar Marktklopfer (< 20) Submitted: 6/03/08 9:58 PM

Once Tysabri gets beyond the 2 year milestone, the PML discount should ease. The pipline is fruitful across Oncology, Immunology, and Neurology. In fact, most analysts agree that Biogen possesses the best MS pipeline in the industry. Also, the pipeline is set up to reduce canibalization less than...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

7 Biogen Idec, Inc. (BIIB)

Avatar NetscribeBiotech (78.76) Submitted: 2/19/07 2:24 AM

Biogen Idec Inc, born in 2003 post the merger of Biogen and Idec Pharmaceuticals, develops, manufactures and commercializes novel therapies. With five approved products viz. Avonex, Rituxan, Tysabr, Amevive, Zevalin and several other products in various stages of clinical trials, it caters to oncolo...More

Replies: 4 | Reply | Permalink

Biogen Idec Inc, born in 2003 post the merger of Biogen and Idec Pharmaceuticals, develops, manufactures and commercializes novel therapies. With five approved products viz. Avonex, Rituxan, Tysabr, Amevive, Zevalin and several other products in various stages of clinical trials, it caters to oncology, neurology, dermatology and rheumatology segment.

This Massachusetts based company recorded solid financial performance in fiscal 2006 with revenues of $2.68 billion an 11% growth and 34% increase in its bottom-line on back of its block-buster drugs Avonex and Rituxan which together contributed about 95% to the top-line.

The main driver for the company going forward would be continued strong sales of its blockbuster portfolio besides growing opportunities in oncology segment which the company seems to be well placed to capitalize. The oncology market is the third largest pharmaceutical market, behind the cardiovascular and CNS therapy areas. It is growing 10% annually and slated to be $53 billion market by 2008. This augurs well for biogen as it is a global leader in development of antibody-based oncology therapeutics. The FDA has also granted priority review status to Biogen Idec/Elan’s multiple sclerosis (MS) drug Antegren which is great news for the company as it highlights the block-buster potential in MS space.

However, there are certain issues that should be of some concern. Chief among them would be lack of late stage pipeline in CNS space and pending lawsuit against the company alleging illegal discounts to boost sales.

The company is profitable, generating positive free cash flows, having block buster drugs and promising pipeline. Nonetheless, with a very high price to earning multiple, it is trading at significant premium to its peers. The growth envisaged by the management seems to be already in the price. Its peer group also seems to be attractively priced. Hence, despite the favorable fundamental outlook the stock may still under perform the market.

CAPS Members

Show Me:

Sort by:

picks per page. CHANGE

Results 1 - 5 of 67 : 1 2 3 4 5 Next » Jump to page:

Recs 0 (BIIB) icanpickm (99.19) Submitted: 7/23/08 11:31 AM : Start Price: $71.94 BIIB Score: -0.50 great quarter, low pe, maybe ready for someone to buy them. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (BIIB) ajm101 (42.67) Submitted: 7/21/08 2:10 PM : Start Price: $67.16 BIIB Score: 4.51 I think the remaining independent biotechs will get a lift if Roche has to lift its bid for Genentech Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (BIIB) SierraBlue (67.50) Submitted: 7/08/08 8:32 PM : Start Price: $62.70 BIIB Score: 13.29 Major Drug Biotechnology Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 1 (BIIB) Marktklopfer (< 20) Submitted: 6/03/08 9:58 PM : Start Price: $61.28 BIIB Score: 23.50 Once Tysabri gets beyond the 2 year milestone, the PML discount should ease. The pipline is fruitful across Oncology, Immunology, and Neurology. In fact, most analysts agree that Biogen possesses the best MS pipeline in the industry. Also, the pipeline is set up to reduce canibalization less than other company's. A buyout within a year gives this stock a 60% gain. An independent Biogen should provide annual gains of 20+% for the next 5 years. Also, the reiterated strategy of achieving 40% of sales from international revenues reduces its risk to US currencies. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (BIIB) berkybucks (81.07) Submitted: 5/27/08 7:02 PM : Start Price: $62.16 BIIB Score: 22.60 Expects revenue growth of 15% and earnings growth of 20%. Raised 2008 outlook 20% over 2007. Beat s&P over the past year. Increasing demand for drugs currently in production. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Results 1 - 5 of 67 : 1 2 3 4 5 Next » Jump to page:

Wall Street

Results 1 - 8 of 8

picks per page. CHANGE Expand All Pitches Collapse All Pitches

Top Pick	Member Name	Member Rating	Start Date	Call	Time Frame	Start Price	Stock Gain	S&P Gain	Score	Pitch
	TrackDodgeCox	98.33	03/31/08 03/31/08		NS	$61.69	+15.71%	-2.85%	+18.56
	TrackBofASec	96.35	01/17/08 01/17/08		NS	$60.61	+17.77%	-6.97%	+24.74
	TrackJimCramer	81.15	11/27/07 11/27/07		3W	$69.75	+2.34%	-10.07%	-12.41
	TrackDeutscheSec	89.63	10/15/07 10/15/07		NS	$81.85	-12.79%	-17.01%	+4.21
	TrackIcahn	94.23	09/30/07 09/30/07		NS	$66.33	+7.61%	-15.97%	+23.59
	TrackEdwardOwens	99.11	09/30/07 09/30/07		NS	$66.33	+7.61%	-15.97%	+23.59
	TrackUBS	94.11	09/13/07 09/13/07		NS	$63.54	+12.34%	-13.69%	-26.03

Results 1 - 8 of 8

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

BIIB Score Leader

TMFBreakerJava
Rating: 99.27
BIIB Score: 107.29

The takeover premium is gone and they continue to have a growing business. The recent label expansion for Tysabri is promising as is the continued clean record (superior clinical experience for patients and no recurrence of PML). They have some other interesting pipeline events upcoming this year. I think they will go higher now.